Items tagged with Latent TB
Rifampin regimen found to be cheaper than isoniazid for latent TB (post)
A 4-month rifampin regimen was found to be cheaper than a 9-month course of isoniazid for the treatment of latent tuberculosis in a cost-comparison study published in the Annals of Internal Medicine. Currently, isoniazid is the standard of treatment in most countries for latent tuberculosis infection. The finding that 4 months rifampin treatment is cheaper adds to previously published evidence that this treatment is as effective, while also significantly safer and more likely to be completed, than 6 months or 9 months isoniazid treatment. These findings have the potential to change the way latent tuberculosis is treated.
Ixekizumab may prevent reactivation of TB in patients with latent TB infection (post)
Ixekizumab, and other antibodies that target interleukin 17 monoclonal antibody (IL-17A), may reduce reactivations of tuberculosis in patients with latent tuberculosis infection (LTBI), according to a study research published in the Journal of the American Academy of Dermatology.
Vitamin D supplementation may not lower risk of TB infection, finds NEJM study (post)
Researchers have found in a new study that vitamin D supplementation did not result in a lower risk of TB infection or TB disease. The study has been published in the New England Journal of Medicine.
COVID-19 could activate latent tuberculosis (post)
For most people in the United States, the only awareness of tuberculosis (TB) may be the skin patch test required to work or volunteer in schools or health care facilities. But that could change during the pandemic.
Self-administered 3HP associated with high treatment completion for latent TB (post)
Self-administered isoniazid-rifapentine taken once weekly — a regimen called 3HP — was associated with higher treatment completion rates for latent tuberculosis infection compared with daily rifampin, according to a study.
Risk predictor could eliminate TB in countries with low transmission (post)
A new online tool which could help eliminate tuberculosis in countries with low transmission rates such as the UK, by identifying who is at highest risk of developing TB, has been developed by UCL researchers.
Latent TB screening and treatment for elderly patients with poorly controlled diabetes mellitus (post)
A programmatic latent tuberculosis infection (LTBI) intervention led to completion rates of 92.7% for LTBI screening and 82.5% for TB preventive therapy (TPT) among elderly patients with poorly controlled diabetes, according to study findings published in Clinical Infectious Diseases.
Study reveals association between CMV and latent TB (post)
U.S. data revealed that cytomegalovirus was independently associated with latent tuberculosis infection, and both were associated with high levels of C-reactive protein, suggesting enhanced systemic inflammation, researchers reported.
Less than half of people with latent TB in the US initiate therapy (post)
Researchers uncovered gaps in the care cascade for latent tuberculosis in the United States, including that less than half of people diagnosed with latent TB in 2016 and 2017 initiated treatment.
Usefulness of monitoring IgG against antigen 85B for prediction of TB development from latency: from an elephant TB analysis (post)
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb); the leading cause of human death due to a single pathogen before the emergence of SARS-CoV-2. In elephants, the infections and deaths with TB have been reported worldwide, and elephant-to-human transmission has also been reported. Therefore, elephant TB is a concern for both conservation of this endangered animal and public health.
Page 10 of 13 · Total posts: 0
←First 9 10 11 Last→